Search

Your search keyword '"Nisticò, Cecilia"' showing total 192 results
Start Over Author "Nisticò, Cecilia"
192 results on '"Nisticò, Cecilia"'

1. Impact of comorbidity on outcome and treatment choice in patients with head and neck squamous cell carcinoma (HNSCC).

Author

Giacinti, Silvana, primary, Giannarelli, Diana, additional, Moi, Rossana, additional, Battista, Michele, additional, Perfetti, Alessandra, additional, Ferrari, Laura, additional, Alò, Piero Luigi, additional, Costanzo, Filippo, additional, Marzetti, Andrea, additional, Cognetti, Francesco, additional, and Nisticò, Cecilia, additional

Published
2024
Full Text
View/download PDF

2. Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial.

Author

Molinelli, Chiara, primary, Delucchi, Virginia, additional, Blondeaux, Eva, additional, Boni, Luca, additional, Poggio, Francesca, additional, Arpino, Grazia, additional, Nisticò, Cecilia, additional, Fabi, Alessandra, additional, De Laurentiis, Michelino, additional, Puglisi, Fabio, additional, Nader Marta, Guilherme, additional, Fozza, Alessandra, additional, Pitto, Francesca, additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2024
Full Text
View/download PDF

3. p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study

Author

Fabi, Alessandra, Mottolese, Marcella, Di Benedetto, Anna, Sperati, Francesca, Ercolani, Cristiana, Buglioni, Simonetta, Nisticò, Cecilia, Ferretti, Gianluigi, Vici, Patrizia, Perracchio, Letizia, Malaguti, Paola, Russillo, Michelangelo, Botti, Claudio, Pescarmona, Edoardo, Cognetti, Francesco, and Terrenato, Irene

Published
2020
Full Text
View/download PDF

4. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

Author

Conte, Benedetta, Bruzzone, Marco, Lambertini, Matteo, Poggio, Francesca, Bighin, Claudia, Blondeaux, Eva, De Laurentiis, Michelino, Valle, Enrichetta, Cognetti, Francesco, Nisticò, Cecilia, De Placido, Sabino, Garrone, Ornella, Gamucci, Teresa, Montemurro, Filippo, Puglisi, Fabio, Cardinali, Barbara, Fregatti, Piero, Miglietta, Loredana, Boccardo, Francesco, Ceppi, Marcello, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

6. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer

Author

Fabi, Alessandra, Alesini, Daniele, Valle, Enrichetta, Moscetti, Luca, Caputo, Roberta, Caruso, Michele, Carbognin, Luisa, Ciccarese, Mariangela, La Verde, Nicla, Arpino, Grazia, Cannita, Katia, Paris, Ida, Santini, Daniele, Montemurro, Filippo, Russillo, Michelangelo, Ferretti, Gianluigi, Filippelli, Gianfranco, Rossello, Rosalba, Fabbri, Agnese, Zambelli, Alberto, Leonardi, Vita, D’Ottavio, Anna Maria, Nisticò, Cecilia, Stani, Simonetta, Giampaglia, Marianna, Scandurra, Giusy, Catania, Giovanna, Malaguti, Paola, Giannarelli, Diana, and Cognetti, Francesco

Published
2018
Full Text
View/download PDF

7. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author

Accurso, Antonello, Agostara, Biagio, Aieta, Michele, Alabiso, Oscar, Alicicco, Maria Grazia, Amadori, Dino, Amaducci, Laura, Amiconi, Gianna, Antuzzi, Giustino, Ardine, Mara, Ardizzoia, Antonio, Aversa, Caterina, Badalamenti, Giuseppe, Barni, Sandro, Basurto, Carlo, Berardi, Rossana, Bergamasco, Cinzia, Bidoli, Paolo, Bighin, Claudia, Biondi, Edoardo, Bisagni, Giancarlo, Boni, Corrado, Borgonovo, Karen, Botta, Mario, Bravi, Stefano, Bruzzi, Paolo, Buono, Giuseppe, Butera, Alfredo, Caldara, Alessia, Candeloro, Giampiero, Cappelletti, Claudia, Cardalesi, Cinzia, Carfora, Elisabetta, Cariello, Anna, Carrozza, Francesco, Cartenì, Giacomo, Caruso, Michele, Casadei, Virginia, Casanova, Claudia, Castori, Luigi, Cavanna, Luigi, Cavazzini, Giovanna, Cazzaniga, Marina, Chilelli, Mario, Chiodini, Paolo, Chiorrini, Silvia, Ciardiello, Fortunato, Ciccarese, Mariangela, Cinieri, Saverio, Clerico, Mario, Coccaro, Mariarosa, Comande, Mario, Corbo, Claudia, Cortino, Giuseppina, Cusenza, Stefania, Daniele, Gennaro, D'arco, Alfonso Maria, D'auria, Giuliana, Dazzi, Claudio, De Angelis, Carmine, de Braud, Filippo, De Feo, Gianfranco, De Matteis, Andrea, De Tursi, Michele, Di Blasio, Anna, di Lucca, Giuseppe, Di Lullo, Liberato, Di Rella, Francesca, Di Renzo, Gianfranco, Di Stefano, Pia, Di Stefano, Aida, Diana, Anna, Donati, Sara, Fabbri, Agnese, Fabi, Alessandra, Faedi, Marina, Farina, Gabriella, Farris, Antonio, Febbraro, Antonio, Fedele, Palma, Federico, Piera, Ferraù, Francesco, Ferretti, Gianluigi, Ferro, Antonella, Floriani, Irene, Forcignanò, Rosachiara, Forciniti, Samantha, Forestieri, Valeria, Fornari, Gianni, Frisinghelli, Michela, Fusco, Vittorio, Gallizzi, Giulia, Galvano, Antonio, Gambardella, Antonio, Gambi, Angelo, Gebbia, Vittorio, Gervasi, Erika, Ghilardi, Mara, Giacobino, Alice, Giardina, Giovanni, Giotta, Francesco, Giraudi, Sara, Giuliano, Mario, Grassadonia, Antonino, Grasso, Donatella, Grosso, Federica, Guizzaro, Lorenzo, Incoronato, Pasquale, Incorvaia, Lorena, Iodice, Giovanni, La Verde, Nicla, Labonia, Vincenzo, Landi, Gabriella, Latorre, Agnese, Leonardi, Vita, Levaggi, Alessia, Limite, Gennaro, Lina Bascialla, Linda, Livi, Lorenzo, Maiello, Evaristo, Mandelli, Daniela, Marcon, Ilaria, Menon, Daniela, Montedoro, Michele, Moraca, Lucia, Moretti, Anna, Morritti, Maria Grazia, Morselli, Patrizia, Mura, Antonella, Mura, Silvia, Musacchio, Michela, Muzio, Alberto, Natale, Donato, Natoli, Clara, Nigro, Cinzia, Nisticò, Cecilia, Nuzzo, Antonio, Orditura, Michele, Orlando, Laura, Pacilio, Carmen, Palumbo, Giuliano, Palumbo, Raffaella, Pasini, Felice, Paterno, Emanuela, Pazzola, Antonio, Pelliccioni, Silvia, Pensabene, Matilde, Perroni, Davide, Pesenti Gritti, Angela, Petrelli, Fausto, Piccirillo, Maria Carmela, Pinotti, Graziella, Pogliani, Claudia, Poli, Davide, Prader, Sonia, Recchia, Francesco, Rizzi, Daniele, Romano, Carmen, Rossello, Rosalba, Rossini, Chiara, Salvucci, Giuseppina, Sanna, Valeria, Santini, Alessandra, Saracchini, Silvana, Savastano, Clementina, Scambia, Giovanni, Schettini, Francesco, Schiavone, Paola, Schirone, Alessio, Seles, Elena, Signoriello, Simona, Signoriello, Giuseppe, Silva, Rosa Rita, Silvestri, Antonia, Simeon, Vittorio, Spagnoletti, Ilaria, Tamberi, Stefano, Teragni, Cristina, Thalmann, Verena, Thomas, Renato, Thomas, Guglielmo, Tienghi, Amelia, Tinari, Nicola, Tinessa, Vincenza, Tomei, Federica, Tonini, Giuseppe, Torri, Valter, Traficante, Divina, Tudini, Marianna, Turazza, Monica, Vignoli, Roberto, Vitale, Maria Giuseppa, Zacchia, Alessandra, Zagarese, Pasquale, Zanni, Alda, Zavallone, Laura, Zavettieri, Maria, Zoboli, Alessandra, De Placido, Sabino, Gallo, Ciro, De Laurentiis, Michelino, Arpino, Grazia, Sarobba, Maria Giuseppa, Riccardi, Ferdinando, Russo, Antonio, Del Mastro, Lucia, Cogoni, Alessio Aligi, Cognetti, Francesco, Gori, Stefania, Foglietta, Jennifer, Frassoldati, Antonio, Amoroso, Domenico, Laudadio, Lucio, Moscetti, Luca, Montemurro, Filippo, Verusio, Claudio, Bernardo, Antonio, Lorusso, Vito, Gravina, Adriano, Moretti, Gabriella, Lauria, Rossella, Lai, Antonella, Mocerino, Carmela, Rizzo, Sergio, Nuzzo, Francesco, Carlini, Paolo, and Perrone, Francesco

Published
2018
Full Text
View/download PDF

8. Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation

Author

Carbognin, Luisa, Sperduti, Isabella, Fabi, Alessandra, Dieci, Maria Vittoria, Kadrija, Dzenete, Griguolo, Gaia, Pilotto, Sara, Guarneri, Valentina, Zampiva, Ilaria, Brunelli, Matteo, Orvieto, Enrico, Nortilli, Rolando, Fiorio, Elena, Parolin, Veronica, Manfrin, Erminia, Caliò, Anna, Nisticò, Cecilia, Pellini, Francesca, Scarpa, Aldo, Pollini, Giovanni Paolo, Conte, Pierfranco, Tortora, Giampaolo, and Bria, Emilio

Published
2017
Full Text
View/download PDF

9. Supplementary Figure S1 from HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Author

Fabi, Alessandra, primary, Di Benedetto, Anna, primary, Metro, Giulio, primary, Perracchio, Letizia, primary, Nisticò, Cecilia, primary, Di Filippo, Franco, primary, Ercolani, Cristiana, primary, Ferretti, Gianluigi, primary, Melucci, Elisa, primary, Buglioni, Simonetta, primary, Sperduti, Isabella, primary, Papaldo, Paola, primary, Cognetti, Francesco, primary, and Mottolese, Marcella, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table S1 from HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Author

Fabi, Alessandra, primary, Di Benedetto, Anna, primary, Metro, Giulio, primary, Perracchio, Letizia, primary, Nisticò, Cecilia, primary, Di Filippo, Franco, primary, Ercolani, Cristiana, primary, Ferretti, Gianluigi, primary, Melucci, Elisa, primary, Buglioni, Simonetta, primary, Sperduti, Isabella, primary, Papaldo, Paola, primary, Cognetti, Francesco, primary, and Mottolese, Marcella, primary

Published
2023
Full Text
View/download PDF

11. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Author

Del Mastro, Lucia, De Placido, Sabino, Bruzzi, Paolo, De Laurentiis, Michele, Boni, Corrado, Cavazzini, Giovanna, Durando, Antonio, Turletti, Anna, Nisticò, Cecilia, Valle, Enrichetta, Garrone, Ornella, Puglisi, Fabio, Montemurro, Filippo, Barni, Sandro, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Giuliano, Mario, Gravina, Adriano, Papaldo, Paola, Bighin, Claudia, Bisagni, Giancarlo, Forestieri, Valeria, and Cognetti, Francesco

Published
2015
Full Text
View/download PDF

12. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Author

Del Mastro, Lucia, primary, Poggio, Francesca, additional, Blondeaux, Eva, additional, De Placido, Sabino, additional, Giuliano, Mario, additional, Forestieri, Valeria, additional, De Laurentiis, Michelino, additional, Gravina, Adriano, additional, Bisagni, Giancarlo, additional, Rimanti, Anita, additional, Turletti, Anna, additional, Nisticò, Cecilia, additional, Vaccaro, Angela, additional, Cognetti, Francesco, additional, Fabi, Alessandra, additional, Gasparro, Simona, additional, Garrone, Ornella, additional, Alicicco, Maria Grazia, additional, Urracci, Ylenia, additional, Mansutti, Mauro, additional, Poletti, Paola, additional, Correale, Pierpaolo, additional, Bighin, Claudia, additional, Puglisi, Fabio, additional, Montemurro, Filippo, additional, Colantuoni, Giuseppe, additional, Lambertini, Matteo, additional, Boni, Luca, additional, Venturini, M, additional, Abate, A, additional, Pastorino, S, additional, Canavese, G, additional, Vecchio, C, additional, Guenzi, M, additional, Lambertini, M, additional, Levaggi, A, additional, Giraudi, S, additional, Accortanzo, V, additional, Floris, C.A., additional, Aitini, E, additional, Fornari, G, additional, Miraglia, S, additional, Buonfanti, G, additional, Cherchi, M.C., additional, Petrelli, F, additional, Vaccaro, A, additional, Magnolfi, E, additional, Contu, A, additional, Labianca, R, additional, Parisi, A, additional, Basurto, C, additional, Cappuzzo, F, additional, Merlano, M, additional, Russo, S, additional, Mansutti, M, additional, Poletto, E, additional, Nardi, M, additional, Grasso, D, additional, Fontana, A, additional, Isa, L, additional, Comandè, M, additional, Cavanna, L, additional, Iacobelli, S, additional, Milani, S, additional, Mustacchi, G, additional, Venturini, S, additional, Scinto, A.F., additional, Sarobba, M.G., additional, Pugliese, P, additional, Bernardo, A, additional, Pavese, I, additional, Coccaro, M, additional, Massidda, B, additional, Ionta, M.T., additional, Nuzzo, A, additional, Laudadio, L, additional, Chiantera, V, additional, Dottori, R, additional, Barduagni, M, additional, Castiglione, F, additional, Ciardiello, F, additional, Tinessa, V, additional, Ficorella, A, additional, Moscetti, L, additional, Vallini, I, additional, Giardina, G, additional, Silva, R, additional, Montedoro, M, additional, Seles, E, additional, Morano, F, additional, Cruciani, G, additional, Adamo, V, additional, Pancotti, A, additional, Palmisani, V, additional, Ruggeri, A, additional, Cammilluzzi, E, additional, Carrozza, F, additional, D'Aprile, M, additional, Brunetti, M, additional, Gallotti, P, additional, Chiesa, E, additional, Testore, F, additional, D'Arco, A, additional, Ferro, A, additional, Jirillo, A, additional, Pezzoli, M, additional, Scambia, G, additional, Iacono, C, additional, Masullo, P, additional, Tomasello, G, additional, Gandini, G, additional, Zoboli, A, additional, Bottero, C, additional, Cazzaniga, M, additional, Genua, G, additional, Palazzo, S, additional, D'Amico, M, additional, and Perrone, D, additional

Published
2022
Full Text
View/download PDF

24. Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients

Author

Fabi, Alessandra, primary, Ferretti, Gianluigi, additional, Malaguti, Paola, additional, Gasparro, Simona, additional, Nisticò, Cecilia, additional, Arpino, Grazia, additional, Papaldo, Paola, additional, Russillo, Michelangelo, additional, Catania, Giovanna, additional, Schettini, Francesco, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2020
Full Text
View/download PDF

25. Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases.

Author

Cicini, Maria Paola, Ferretti, Gianluigi, Morace, Nicola, Nisticò, Cecilia, Cognetti, Francesco, and Rulli, Francesco

Subjects
CARDIOTOXICITY, ECHOCARDIOGRAPHY, PROTEIN kinase inhibitors, HEART block, CARDIAC pacing, DUCTAL carcinoma, BREAST cancer, CARDIAC pacemakers, HORMONE receptor positive breast cancer
Abstract

Introduction: A wide spectrum of cardiovascular (CV) toxicity is associated with anticancer treatment, and nearly all chemotherapeutic agents can elicit CV toxicity. Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6Is) have become standard of care in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC). CV side effects are uncommon with CDK4/6Is and only include QT prolongation, with a low incidence rate. Case Presentation: This paper describes 2 cases of new-onset second-degree type 2 atrioventricular (AV) blocks requiring permanent cardiac pacing involving 2 women with MBC receiving ribociclib or abemaciclib. Both our patients had no known history or risk factors of cardiac disease and a normal 12-lead resting electrocardiogram (ECG) when diagnosed with breast adenocarcinoma. Both patients have been subjected to surveillance for cardiotoxicity with serial ECG and echocardiography. No left ventricular dysfunction or arrhythmia was found during the follow-up, and cardiac biomarkers were normal. Conclusion: To our knowledge, these are the first cases reported in the literature of new-onset advanced AV blocks in patients under treatment with CDK4/6Is, suggesting the clinical relevance of a more frequent ECG monitoring, besides the QT interval, in these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?

Author

Papaldo, Paola, Ferretti, Gianluigi, Di Cosimo, Serena, Giannarelli, Diana, Marolla, Paolo, Lopez, Massimo, Cortesi, Enrico, Antimi, Mauro, Terzoli, Edmondo, Carlini, Paolo, Vici, Patrizia, Botti, Claudio, Di Lauro, Luigi, Naso, Giuseppe, Nisticò, Cecilia, Mottolese, Marcella, Di Filippo, Franco, Ruggeri, Enzo Maria, Ceribelli, Anna, and Cognetti, Francesco

Published
2006
Full Text
View/download PDF

30. Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide

Author

Papaldo, Paola, Lopez, Massimo, Marolla, Paolo, Cortesi, Enrico, Antimi, Mauro, Terzoli, Edmondo, Vici, Patrizia, Barone, Carlo, Ferretti, Gianluigi, Di Cosimo, Serena, Carlini, Paolo, Nisticò, Cecilia, Conti, Francesca, Di Lauro, Luigi, Botti, Claudio, Di Filippo, Franco, Fabi, Alessandra, Giannarelli, Diana, and Calabresi, Federico

Published
2005
Full Text
View/download PDF

34. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Author

Papaldo, Paola, Lopez, Massimo, Cortesi, Enrico, Cammilluzzi, Eugenio, Antimi, Mauro, Terzoli, Edmondo, Lepidini, Giuseppe, Vici, Patrizia, Barone, Carlo, Ferretti, Gianluigi, Di Cosimo, Serena, Nisticò, Cecilia, Carlini, Paolo, Conti, Francesca, Di Lauro, Luigi, Botti, Claudio, Vitucci, Carlo, Fabi, Alessandra, Giannarelli, Diana, and Marolla, Paolo

Published
2003

37. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Author

Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, and Cognetti Francesco

Subjects
Maintenance Bevacizumab, Antiangiogenic agents, HER2 negative metastatic breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT. Methods Thirty-five patients who experienced a response after first-line BT, were given mBev at the dose of 15 mg/kg every 3 weeks. Among 30 pts with hormonal receptor-positive metastatic breast cancer (MBC), 20 (66.6%) received HT with mBev (mHTBev). Objective of the study was the outcome and safety of mBev and in two groups of patients receiving HT or not. Results Complete response and partial response was achieved/maintained in 4 (11.4%) and 13 (37.1%) patients, respectively (overall response rate: 48.5%). Clinical benefit was obtained on 23 patients (65.7%). Median of mBev PFS and clinical benefit were 6.8 months (95% CI: 0.8-12.7) and 17.1 months (95% CI :12.2-21.9), respectively. Median PFS of patients who received mHTBev was longer than mBev without HT (13 months and 4.1 months, respectively, p = 0.05). The most common severe toxicities were proteinuria (11.4%) and hypertension (8.5%). No additional toxicity was observed with HTBev. Conclusion Maintenance bevacizumab with or without anti-hormonal therapy in patients with hormone receptor positive breast cancer is tolerable and associated with long-term clinical outcome; these results encourage the strategy of prolonging bevacizumab until progression in combination with anti-hormonal agents.

Published
2012
Full Text
View/download PDF

38. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Author

Rossi, Valentina, primary, Berchialla, Paola, additional, Giannarelli, Diana, additional, Nisticò, Cecilia, additional, Ferretti, Gianluigi, additional, Gasparro, Simona, additional, Russillo, Michelangelo, additional, Catania, Giovanna, additional, Vigna, Leonardo, additional, Mancusi, Rossella Letizia, additional, Bria, Emilio, additional, Montemurro, Filippo, additional, Cognetti, Francesco, additional, and Fabi, Alessandra, additional

Published
2019
Full Text
View/download PDF

39. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Author

Russillo Michelangelo, Nisticò Cecilia, Milella Michele, Carlini Paolo, Sperduti Isabella, Fabi Alessandra, Puglisi Fabio, Vaccaro Vanja, Bria Emilio, Cuppone Federica, Papaldo Paola, Ferretti Gianluigi, Aapro Matti, Giannarelli Diana, and Cognetti Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile. Methods A literature-based meta-analysis to quantify the magnitude of benefit and safety of adding bevacizumab to chemotherapy for advanced breast cancer patients was conducted. Meta-regression and sensitivity analyses were also performed to identify additional predictors of outcome and to assess the influence of trial design. Results Five trials (3,841 patients) were gathered. A significant interaction according to treatment line was found for progression-free survival (PFS, p = 0.027); PFS was significantly improved for 1st line (Hazard Ratio, HR 0.68, p < 0.0001), with a 1-yr absolute difference (AD) of 8.4% (number needed to treat, NNT 12). A non-significant trend was found in overall survival (OS), and in PFS for 2nd line. Responses were improved with the addition of bevacizumab, without interaction between 1st line (Relative Risk, RR 1.46, p < 0.0001) and 2nd line (RR 1.58, p = 0.05). The most important toxicity was hypertension, accounting for a significant AD of 4.5% against bevacizumab (number needed to harm, NNH 22). Other significant, although less clinically meaningful, adverse events were proteinuria, neurotoxicity, febrile neutropenia, and bleeding. At the meta-regression analysis for 1st-line, more than 3 metastatic sites (p = 0.032), no adjuvant chemotherapy (p = 0.00013), negative hormonal receptor status (p = 0.009), and prior anthracyclines-exposure (p = 0.019), did significantly affect PFS. Conclusions Although with heterogeneity, the addition of bevacizumab to 1st-line chemotherapy significantly improves PFS, and overall activity. Hypertension should be weighted with the overall benefit on the individual basis.

Published
2011
Full Text
View/download PDF

40. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials

Author

Pinnarò Paola, Bracarda Sergio, Sperduti Isabella, Ruggeri Enzo, Nisticò Cecilia, Milella Michele, Vaccaro Vanja, Giannarelli Diana, Bria Emilio, Cuppone Federica, Lanzetta Gaetano, Muti Paola, Cognetti Francesco, and Carlini Paolo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients affected by locally advanced prostate cancer. In order to determine if difference exists according to the hormonal treatment duration, a literature-based meta-analysis was performed. Methods Relative risks (RR) were derived through a random-effect model. Differences in primary (biochemical failure, BF; cancer-specific survival, CSS), and secondary outcomes (overall survival, OS; local or distant recurrence, LR/DM) were explored. Absolute differences (AD) and the number needed to treat (NNT) were calculated. Heterogeneity, a meta-regression for clinic-pathological predictors and a correlation test for surrogates were conducted. Results Five trials (3,424 patients) were included. Patient population ranged from 267 to 1,521 patients. The longer hormonal treatment significantly improves BF (with significant heterogeneity) with an absolute benefit of 10.1%, and a non significant trend in CSS. With regard to secondary end-points, the longer hormonal treatment significantly decrease both the LR and the DM with an absolute difference of 11.7% and 11.5%. Any significant difference in OS was observed. None of the three identified clinico-pathological predictors (median PSA, range 9.5-20.35, Gleason score 7-10, 27-55% patients/trial, and T3-4, 13-77% patients/trial), did significantly affect outcomes. At the meta-regression analysis a significant correlation between the overall treatment benefit in BF, CSS, OS, LR and DM, and the length of the treatment was found (p≤0.03). Conclusions Although with significant heterogeneity (reflecting different patient' risk stratifications), a longer hormonal treatment duration significantly decreases biochemical, local and distant recurrences, with a trend for longer cancer specific survival.

Published
2010
Full Text
View/download PDF

41. Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.

Author

Fabi, Alessandra, Terrenato, Irene, Vidiri, Antonello, Villani, Veronica, Tanzilli, Antonio, Airoldi, Mario, Pedani, Fulvia, Magri, Valentina, Palleschi, Michela, Donadio, Michela, Catania, Giovanni, Nisticò, Cecilia, Carapella, Carmine, Rudà, Roberta, Pace, Andrea, Maschio, Marta, Telera, Stefano, Cognetti, Francesco, Magrì, Valentina, and AINO (Associazione Italiana Neuro-Oncologia)

Subjects
SURVIVAL, RESEARCH, HETEROCYCLIC compounds, PROGNOSIS, EVALUATION research, BRAIN tumors, COMPARATIVE studies, BREAST tumors, KETONES, LONGITUDINAL method
Abstract

Background: Eribulin shows some activity in controlling brain metastasis in breast cancer. Methods: This observational, multicenter study evaluated brain disease control rates, survival and safety in patients with brain metastatic breast cancer treated with eribulin in clinical practice. Results: A total of 34 patients were enrolled (mean age 49 years, 91% with visceral metastases) and 29 were evaluable for brain disease. Fourteen achieved disease control and showed a longer time without progression: 10 months (95% CI: 2.3-17.7) versus 4 months (95% CI: 3.3-4.7) in the control group (p = 0.029). Patients with clinical benefits at 6 months had longer survival. Leukopenia and neutropenia were the most frequent grade 3-4 toxicities. Conclusion: Eribulin confirms its effectiveness in patients with brain metastatic breast cancer. Further studies on larger cohorts are needed to confirm the results. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author

De Placido, Sabino, primary, Gallo, Ciro, additional, De Laurentiis, Michelino, additional, Bisagni, Giancarlo, additional, Arpino, Grazia, additional, Sarobba, Maria Giuseppa, additional, Riccardi, Ferdinando, additional, Russo, Antonio, additional, Del Mastro, Lucia, additional, Cogoni, Alessio Aligi, additional, Cognetti, Francesco, additional, Gori, Stefania, additional, Foglietta, Jennifer, additional, Frassoldati, Antonio, additional, Amoroso, Domenico, additional, Laudadio, Lucio, additional, Moscetti, Luca, additional, Montemurro, Filippo, additional, Verusio, Claudio, additional, Bernardo, Antonio, additional, Lorusso, Vito, additional, Gravina, Adriano, additional, Moretti, Gabriella, additional, Lauria, Rossella, additional, Lai, Antonella, additional, Mocerino, Carmela, additional, Rizzo, Sergio, additional, Nuzzo, Francesco, additional, Carlini, Paolo, additional, Perrone, Francesco, additional, Accurso, Antonello, additional, Agostara, Biagio, additional, Aieta, Michele, additional, Alabiso, Oscar, additional, Alicicco, Maria Grazia, additional, Amadori, Dino, additional, Amaducci, Laura, additional, Amiconi, Gianna, additional, Antuzzi, Giustino, additional, Ardine, Mara, additional, Ardizzoia, Antonio, additional, Aversa, Caterina, additional, Badalamenti, Giuseppe, additional, Barni, Sandro, additional, Basurto, Carlo, additional, Berardi, Rossana, additional, Bergamasco, Cinzia, additional, Bidoli, Paolo, additional, Bighin, Claudia, additional, Biondi, Edoardo, additional, Boni, Corrado, additional, Borgonovo, Karen, additional, Botta, Mario, additional, Bravi, Stefano, additional, Bruzzi, Paolo, additional, Buono, Giuseppe, additional, Butera, Alfredo, additional, Caldara, Alessia, additional, Candeloro, Giampiero, additional, Cappelletti, Claudia, additional, Cardalesi, Cinzia, additional, Carfora, Elisabetta, additional, Cariello, Anna, additional, Carrozza, Francesco, additional, Cartenì, Giacomo, additional, Caruso, Michele, additional, Casadei, Virginia, additional, Casanova, Claudia, additional, Castori, Luigi, additional, Cavanna, Luigi, additional, Cavazzini, Giovanna, additional, Cazzaniga, Marina, additional, Chilelli, Mario, additional, Chiodini, Paolo, additional, Chiorrini, Silvia, additional, Ciardiello, Fortunato, additional, Ciccarese, Mariangela, additional, Cinieri, Saverio, additional, Clerico, Mario, additional, Coccaro, Mariarosa, additional, Comande, Mario, additional, Corbo, Claudia, additional, Cortino, Giuseppina, additional, Cusenza, Stefania, additional, Daniele, Gennaro, additional, D'arco, Alfonso Maria, additional, D'auria, Giuliana, additional, Dazzi, Claudio, additional, De Angelis, Carmine, additional, de Braud, Filippo, additional, De Feo, Gianfranco, additional, De Matteis, Andrea, additional, De Tursi, Michele, additional, Di Blasio, Anna, additional, di Lucca, Giuseppe, additional, Di Lullo, Liberato, additional, Di Rella, Francesca, additional, Di Renzo, Gianfranco, additional, Di Stefano, Pia, additional, Di Stefano, Aida, additional, Diana, Anna, additional, Donati, Sara, additional, Fabbri, Agnese, additional, Fabi, Alessandra, additional, Faedi, Marina, additional, Farina, Gabriella, additional, Farris, Antonio, additional, Febbraro, Antonio, additional, Fedele, Palma, additional, Federico, Piera, additional, Ferraù, Francesco, additional, Ferretti, Gianluigi, additional, Ferro, Antonella, additional, Floriani, Irene, additional, Forcignanò, Rosachiara, additional, Forciniti, Samantha, additional, Forestieri, Valeria, additional, Fornari, Gianni, additional, Frisinghelli, Michela, additional, Fusco, Vittorio, additional, Gallizzi, Giulia, additional, Galvano, Antonio, additional, Gambardella, Antonio, additional, Gambi, Angelo, additional, Gebbia, Vittorio, additional, Gervasi, Erika, additional, Ghilardi, Mara, additional, Giacobino, Alice, additional, Giardina, Giovanni, additional, Giotta, Francesco, additional, Giraudi, Sara, additional, Giuliano, Mario, additional, Grassadonia, Antonino, additional, Grasso, Donatella, additional, Grosso, Federica, additional, Guizzaro, Lorenzo, additional, Incoronato, Pasquale, additional, Incorvaia, Lorena, additional, Iodice, Giovanni, additional, La Verde, Nicla, additional, Labonia, Vincenzo, additional, Landi, Gabriella, additional, Latorre, Agnese, additional, Leonardi, Vita, additional, Levaggi, Alessia, additional, Limite, Gennaro, additional, Lina Bascialla, Linda, additional, Livi, Lorenzo, additional, Maiello, Evaristo, additional, Mandelli, Daniela, additional, Marcon, Ilaria, additional, Menon, Daniela, additional, Montedoro, Michele, additional, Moraca, Lucia, additional, Moretti, Anna, additional, Morritti, Maria Grazia, additional, Morselli, Patrizia, additional, Mura, Antonella, additional, Mura, Silvia, additional, Musacchio, Michela, additional, Muzio, Alberto, additional, Natale, Donato, additional, Natoli, Clara, additional, Nigro, Cinzia, additional, Nisticò, Cecilia, additional, Nuzzo, Antonio, additional, Orditura, Michele, additional, Orlando, Laura, additional, Pacilio, Carmen, additional, Palumbo, Giuliano, additional, Palumbo, Raffaella, additional, Pasini, Felice, additional, Paterno, Emanuela, additional, Pazzola, Antonio, additional, Pelliccioni, Silvia, additional, Pensabene, Matilde, additional, Perroni, Davide, additional, Pesenti Gritti, Angela, additional, Petrelli, Fausto, additional, Piccirillo, Maria Carmela, additional, Pinotti, Graziella, additional, Pogliani, Claudia, additional, Poli, Davide, additional, Prader, Sonia, additional, Recchia, Francesco, additional, Rizzi, Daniele, additional, Romano, Carmen, additional, Rossello, Rosalba, additional, Rossini, Chiara, additional, Salvucci, Giuseppina, additional, Sanna, Valeria, additional, Santini, Alessandra, additional, Saracchini, Silvana, additional, Savastano, Clementina, additional, Scambia, Giovanni, additional, Schettini, Francesco, additional, Schiavone, Paola, additional, Schirone, Alessio, additional, Seles, Elena, additional, Signoriello, Simona, additional, Signoriello, Giuseppe, additional, Silva, Rosa Rita, additional, Silvestri, Antonia, additional, Simeon, Vittorio, additional, Spagnoletti, Ilaria, additional, Tamberi, Stefano, additional, Teragni, Cristina, additional, Thalmann, Verena, additional, Thomas, Renato, additional, Thomas, Guglielmo, additional, Tienghi, Amelia, additional, Tinari, Nicola, additional, Tinessa, Vincenza, additional, Tomei, Federica, additional, Tonini, Giuseppe, additional, Torri, Valter, additional, Traficante, Divina, additional, Tudini, Marianna, additional, Turazza, Monica, additional, Vignoli, Roberto, additional, Vitale, Maria Giuseppa, additional, Zacchia, Alessandra, additional, Zagarese, Pasquale, additional, Zanni, Alda, additional, Zavallone, Laura, additional, Zavettieri, Maria, additional, and Zoboli, Alessandra, additional

Published
2018
Full Text
View/download PDF

43. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Author

Gamucci, Teresa, Mentuccia, Lucia, Natoli, Clara, Sperduti, Isabella, Cassano, Alessandra, Michelotti, Andrea, Di Lauro, Luigi, Sergi, Domenico, Fabi, Alessandra, Sarobba, Maria G., Marchetti, Paolo, Barba, Maddalena, Magnolfi, Emanuela, Maugeri‐Saccà, Marcello, Rossi, Ernesto, Sini, Valentina, Grassadonia, Antonino, Pellegrini, Domenica, Astone, Antonino, Nisticò, Cecilia, Angelini, Franco, Vaccaro, Angela, Pellegrino, Arianna, De Angelis, Claudia, Palleschi, Michela, Moscetti, Luca, Bertolini, Ilaria, Buglioni, Simonetta, Giordano, Antonio, Pizzuti, Laura, and Vici, Patrizia

Subjects
Adult, Paclitaxel, Receptor, ErbB-2, Physiology, Clinical Biochemistry, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, ErbB-2, 80 and over, Humans, Original Research Article, Neoplasm Metastasis, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Settore MED/06 - ONCOLOGIA MEDICA, Medicine (all), Cell Biology, Middle Aged, Bevacizumab, Treatment Outcome, Multivariate Analysis, Female, Receptor
Abstract

Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel‐bevacizumab and of maintenance therapy with bevacizumab (BM) and endocrine therapy (ET) in the real‐world practice. We identified 314 HER2‐negative MBC patients treated in 12 cancer centers. Overall, the median PFS and OS were 14 and 40 months, respectively. Among the 254 patients potentially eligible for BM, 183 received BM after paclitaxel discontinuation until progression/toxicity. PFS and OS were improved in patients who had received BM in comparison with those potentially eligible but who did not receive BM (P

Published
2017

44. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Author

Fabi, Alessandra, primary, Giannarelli, Diana, additional, Moscetti, Luca, additional, Santini, Daniele, additional, Zambelli, Alberto, additional, Laurentiis, Michelino De, additional, Caruso, Michele, additional, Generali, Daniele, additional, Valle, Enrichetta, additional, Leonardi, Vita, additional, Cannita, Katia, additional, Arpino, Grazia, additional, Filippelli, Gianfranco, additional, Ferretti, Gianluigi, additional, Giampaglia, Marianna, additional, Montemurro, Filippo, additional, Nisticò, Cecilia, additional, Gasparro, Simona, additional, and Cognetti, Francesco, additional

Published
2017
Full Text
View/download PDF

45. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Author

Gamucci, Teresa, primary, Mentuccia, Lucia, additional, Natoli, Clara, additional, Sperduti, Isabella, additional, Cassano, Alessandra, additional, Michelotti, Andrea, additional, Di Lauro, Luigi, additional, Sergi, Domenico, additional, Fabi, Alessandra, additional, Sarobba, Maria G., additional, Marchetti, Paolo, additional, Barba, Maddalena, additional, Magnolfi, Emanuela, additional, Maugeri-Saccà, Marcello, additional, Rossi, Ernesto, additional, Sini, Valentina, additional, Grassadonia, Antonino, additional, Pellegrini, Domenica, additional, Astone, Antonino, additional, Nisticò, Cecilia, additional, Angelini, Franco, additional, Vaccaro, Angela, additional, Pellegrino, Arianna, additional, De Angelis, Claudia, additional, Palleschi, Michela, additional, Moscetti, Luca, additional, Bertolini, Ilaria, additional, Buglioni, Simonetta, additional, Giordano, Antonio, additional, Pizzuti, Laura, additional, and Vici, Patrizia, additional

Published
2016
Full Text
View/download PDF

46. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

Author

Fabi, Alessandra, primary, Giannarelli, Diana, additional, Malaguti, Paola, additional, Ferretti, Gianluigi, additional, Vari, Sabrina, additional, Papaldo, Paola, additional, Nisticò, Cecilia, additional, Caterino, Mauro, additional, De Vita, Roy, additional, Mottolese, Marcella, additional, Cognetti, Francesco, additional, and Iacorossi, Laura, additional

Published
2015
Full Text
View/download PDF

47. Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.

Author

Kadrija, Dzenete, Pilotto, Sara, Zampiva, Ilaria, Carbognin, Luisa, Nortilli, Rolando, Fiorio, Elena, Parolin, Veronica, Tortora, Giampaolo, Bria, Emilio, Brunelli, Matteo, Manfrin, Erminia, Caliò, Anna, Scarpa, Aldo, Pellini, Francesca, Pollini, Giovanni Paolo, Sperduti, Isabella, Fabi, Alessandra, Nisticò, Cecilia, Dieci, Maria Vittoria, and Griguolo, Gaia

Subjects
LOBULAR carcinoma, KI-67 antigen, CANCER cell proliferation, BREAST cancer prognosis, BIOMARKERS, HISTOPATHOLOGY, PROGRESSION-free survival, BREAST cancer surgery, PROGNOSIS
Abstract

Introduction The intent of this analysis was to investigate and validate the prognostic potential of Ki67 in a multi-center series of patients affected by early stage ‘pure’ invasive lobular carcinoma (ILC). Methods Clinical-pathological data of patients affected by ILC were correlated with overall survival and disease-free survival (OS/DFS); data from a parallel invasive ductal carcinoma (IDC) patients' cohort were gathered as well. The maximally selected Log-Rank statistics analysis was applied to Ki67 continuous variable to estimate the appropriate cut-off. The Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was performed as well. Results Data from overall 1097 (457/222 ILC: training/validation set; 418 IDC) patients were gathered. The identified optimal Ki67 cut-offs were 4% and 14% for DFS in ILC and IDC cohort, respectively. In ILC patients, the Ki67 cut-off was an independent OS predictor. Ten-years OS and DFS were 89.9% and 77.2% ( p = 0.007 ) and 79.4% and 69.2% ( p = 0.03 ) for patients with Ki67 ≤ 4% and >4%, respectively. In IDC patients, 10-years OS was 93.8% and 71.7%, p = 0.02, DFS was 84.0% and 52.6%, p = 0.0003 , for patients with Ki67 ≤ 14% and >14%, respectively. In the validation set, the optimal Ki67 OS cut-off was 5%. The STEPP analysis showed that in the presence of low Ki67 values, IDC patients have a better DFS than ILC patients, while with the increase of values the prognosis tends to overlap. Conclusions Despite the retrospective design of the study, the prognostic relevance of Ki67 (as well as its optimal cut-off) seems to significantly differ according to breast cancer histology. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

Author

Fabi, Alessandra, primary, Merola, Roberta, additional, Ferretti, Gianluigi, additional, Di Benedetto, Anna, additional, Antoniani, Barbara, additional, Ercolani, Cristiana, additional, Nisticò, Cecilia, additional, Papaldo, Paola, additional, Ciccarese, Mariangela, additional, Sperduti, Isabella, additional, Vici, Patrizia, additional, Marino, Mirella, additional, Gori, Stefania, additional, Botti, Claudio, additional, Malaguti, Paola, additional, Cognetti, Francesco, additional, and Mottolese, Marcella, additional

Published
2013
Full Text
View/download PDF

49. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Author

Cuppone, Federica, primary, Bria, Emilio, additional, Vaccaro, Vanja, additional, Puglisi, Fabio, additional, Fabi, Alessandra, additional, Sperduti, Isabella, additional, Carlini, Paolo, additional, Milella, Michele, additional, Nisticò, Cecilia, additional, Russillo, Michelangelo, additional, Papaldo, Paola, additional, Ferretti, Gianluigi, additional, Aapro, Matti, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2011
Full Text
View/download PDF

50. HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

Author

Fabi, Alessandra, primary, Di Benedetto, Anna, additional, Metro, Giulio, additional, Perracchio, Letizia, additional, Nisticò, Cecilia, additional, Di Filippo, Franco, additional, Ercolani, Cristiana, additional, Ferretti, Gianluigi, additional, Melucci, Elisa, additional, Buglioni, Simonetta, additional, Sperduti, Isabella, additional, Papaldo, Paola, additional, Cognetti, Francesco, additional, and Mottolese, Marcella, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results